Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 2Phase NA 1Phase 4 1Phase 3 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1Dermatologic 1

Conditions

Prostatic Neoplasms 28Lymphoma, Large B-Cell, Diffuse 21Lymphoma 16Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Immunoblastic Lymphadenopathy 4Recurrence 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Waldenstrom Macroglobulinemia 2Plasmablastic Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, T-Cell 2Hematologic Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Vincristine 5Doxorubicin 5Cyclophosphamide 5Prednisone 4Peripheral Blood Stem Cell Transplantation 4Rituximab 3Ifosfamide 3Everolimus 3Etoposide 3Carboplatin 3romidepsin 2pembrolizumab 2fludarabine phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Lenalidomide 2Immunohistochemistry 2Gene Expression Profiling 2Cyclosporine 2Clofarabine 210-propargyl-10-deazaaminopterin 2veliparib 1prednylidene 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1etoposide phosphate 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoblastic Lymphadenopathy × Prednisone × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT02561273 2023-12-13

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

University of Nebraska

Phase 1/2 Completed
54 enrolled 14 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT00787527 2014-09-09

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
14 enrolled 8 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT00363090 2013-09-20

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
84 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡